OBJ Limited

leaders in magnetic micro-array drug delivery

18 May 2015

BODYGUARD CLINICAL TRIAL TO COMMENCE

OBJ Limited (ASX: OBJ) is pleased to report that the major double-blind clinical trial of the Company's Bodyguard product will kick off this week.

The trial is being conducted by the University of Queensland. The clinical trial will compare the efficacy of the Company's KneeGuard product in the restoration of pain-free knee functionality with one of the world's largest selling topical non-steroidal anti-inflammatory drug products. Joint aging and the restoration of healthy lifestyles in aging populations represents a major growth market opportunity for the Company.

Results are expected to become available later in the year.

The clinical trial commenced later than initially planned due to technical challenges in creating the world's first drug-free joint maintenance and restoration orthotic device.

The KneeGuard product, while appearing simple and easy to use, combines a number of key innovations in formulation technology, product molding, packaging and physiological stimulation.

The Company has entered into an exclusive Evaluation Agreement with Procter & Gamble ("P&G"), the world's largest consumer products company, but has more recently been approached by three additional multi-national corporations with interests in the global musculoskeletal health sector. This is a very encouraging sign in the product's potential with multiple parties already expressing their early interest.

OTHER ACTIVITIES

Procter & Gamble

The Company is also pleased to report the commencement of a second human clinical efficacy study by P&G Cincinnati to evaluate the clinical efficacy and consumer benefits of the Company's technology for another of P&G's major skincare brands. The increased interest in OBJ technologies by various P&G franchises follows the successful launch of the SK-II Eye Wand products during 2014.

The Company is currently working closely with P&G to finalise additional Work Plans with a number of P&G franchises across a diverse range of brands and market sectors. The excellent working relationship with such a major company as P&G continues to grow and, as demonstrated by the fast product launches with SKII, continues to offer significant early opportunities for the Company.

The Company will also be participating and contributing to a P&G future manufacturing summit in Singapore in June. The summit will focus on utilising the team that OBJ assembled for the SK-II Eye wand project that delivered the innovation product in a very short time frame. The summit will focus on the coordination of these resources to deliver even greater level of product innovation into the future.

For personal use only

ABN 72 056 482 636
284 Oxford Street, Leederville 6007 Perth, Western Australia
Telephone +61 8 9443 3011 Facsimile +61 8 9443 9960
www.obj.com.au

OBJ Limited

leaders in magnetic micro-array drug delivery



Surface Hygiene Program

The Company's Surface Hygiene program will move to the next level in the coming weeks with finalisation of the new study protocols by Professor Tom Riley, Professor in the School of Pathology and Laboratory Medicine at the University of Western Australia. He is Head of the Centre of Research Excellence in Reducing Healthcare Associated Infections. The study will evaluate the ability of the Company's special magnetic microarrays to drive antiseptic agents deep into household, hospital and industry surfaces to increase hygiene outcomes. Surface disinfection is a multi-billion dollar industry and the use of a physical science to improve hygiene outcomes rather ever increasingly toxic chemistry is believed to be a world's first.

New Technology Platform

The Company is currently working with its patent attorneys in the lodgment of patent protection for a new technology platform for enhanced skin penetration of cosmetic, skin care and therapeutic molecules.

The new technology, also based on weak atomic force science, has been developed by the Company's scientific team to support the growing enquiries from major European, US and Asian corporations seeking access to the Company's technology innovations.

Laboratory Facility Expansion

The Company is undertaking an expansion program to increase the laboratory space and human resources at its Perth headquarters. The expansion program will see a near doubling of the Skin Science Laboratory space and will allow the Company to substantially increase its ability to meet the needs of current and future partnering and development programs. The investment in additional development capabilities will significantly shorten the timelines for deliverables with OBJ's various partners.

- ENDS –

About OBJ:

OBJ develops proprietary magnetic micro-array drug delivery and product enhancement technologies for the pharmaceutical, healthcare and consumer goods sectors.

OBJ partners companies in the design and development of next generation products using physical science rather than chemistry to provide new levels of product performance without the cost of reformulation or new ingredient approvals.

OBJ offers a portfolio of proprietary technologies and supports partners by providing IP-protected market exclusivity, expertise in magnetic array design, feasibility and efficacy and claims testing, engineering and production.

About OBJ's Technologies:

OBJ has developed a platform of physical enhancement technologies based on low-cost magnetic micro-arrays that influence the movement and penetration of drugs, active ingredients and formulations at the molecular level.

Complex 3-D array and moving magnetic fields have the ability to repulse certain molecules to enhance diffusion and to alter the permeability of certain biological and non-biological targets.

OBJ develops low cost micro-array film technology that utilises diamagnetic repulsion, induced permeation and energy redirection to offer a new way of managing the speed, depth of penetration and delivery of active ingredients in a wide range of pharmaceutical and consumer products.

For personal use only

ABN 72 056 482 636
284 Oxford Street, Leederville 6007 Perth, Western Australia
Telephone +61 8 9443 3011 Facsimile +61 8 9443 9960
www.obj.com.au

OBJ Limited

leaders in magnetic micro-array drug delivery



Forward-looking Statements

This announcement contains certain "forward-looking statements" concerning OBJ. Where OBJ expresses or implies an expectation or belief as to future events or results, such expectation or belief is expressed in good faith and believed to have a reasonable basis.

Forward-looking statements provided in this announcement are based on assumptions and contingencies which are subject to change without notice. Such forward-looking statements including statements regarding intentions, planned events and potential results are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance.

There can be no assurance that actual outcomes will not differ materially from these forward-looking statements, and there are risks associated with OBJ and the industry which may affect the accuracy of the forward-looking statements. OBJ does not undertake any obligation to release publicly any revisions to any forward-looking statement to reflect events or circumstances after the date of this announcement or to reflect the occurrence of unanticipated events, except as may be required under applicable securities laws.

For more information:

OBJ Ltd:

Mr Glyn Denison
Director

Telephone +618 9443 3011
Email info@obj.com.au
Web www.obj.com.au

For personal use only